This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Here's Why You Should Hold on to Integra (IART) Stock for Now
by Zacks Equity Research
Investors are optimistic about Integra's (IART) better-than-expected results and robust segmental performance.
Integra's (IART) Q4 Earnings Top Estimates, Gross Margin Drops
by Zacks Equity Research
Integra (IART) records strong recovery in order demand in Q4 on broad-based strength in Neurosurgery and sales from the company's new CereLink ICP monitoring.
Integra LifeSciences (IART) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Integra (IART) delivered earnings and revenue surprises of 1.20% and 0.49%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Integra (IART) Announces Preliminary Q4 & '21 Sales Results
by Zacks Equity Research
Integra's (IART) preliminary revenue results and recent plans to implement a $125-million share repurchase instill investor optimism.
Here's Why You Should Hold on to Integra (IART) Stock for Now
by Zacks Equity Research
Investors are optimistic about Integra's (IART) strong third-quarter performance and ongoing recovery across its business.
Integra (IART) Businesses Rebound Despite Supply Issues
by Zacks Equity Research
Integra's (IART) ongoing sales recovery across geographies and product lines looks encouraging.
Integra (IART) Down 13.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Integra (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Hold on to Integra (IART) Stock for Now
by Zacks Equity Research
Investors are optimistic about Integra (IART) given its better-than-expected results and robust performance of the CSS arm in the third quarter.
Integra (IART) Q3 Earnings Top Estimates, 2021 EPS View Up
by Zacks Equity Research
Integra (IART) reports better-than-expected earnings and revenues with robust demand for the company's products driving the top line in third-quarter 2021.
Integra LifeSciences (IART) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Integra (IART) delivered earnings and revenue surprises of 19.44% and 0.52%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Integra LifeSciences (IART) Q3 Earnings Expected to Decline
by Zacks Equity Research
Integra (IART) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Integra (IART) Up 1.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Integra (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain Integra (IART) Stock for Now
by Zacks Equity Research
Solid performance across the CSS and Tissue Technologies segments is driving the top line for Integra (IART).
Integra LifeSciences (IART) is a Top-Ranked Momentum Stock: Should You Buy?
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Integra (IART) Q2 Earnings Top Estimates, 2021 Guidance Up
by Zacks Equity Research
Integra (IART) reports better-than-expected revenues with strong segmental performance driving the top line in second-quarter 2021.
Integra LifeSciences (IART) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Integra (IART) delivered earnings and revenue surprises of 17.91% and 3.69%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Medical Device Stocks' Earnings on Jul 28: TMO, ALGN & More
by Urmimala Biswas
The sector's Q2 results are likely to reflect solid earnings and revenue growth on strong base business recovery.
Integra LifeSciences (IART) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Integra (IART) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Integra (IART) Releases Favorable PriMatrix Clinical Outcome
by Zacks Equity Research
Integra's (IART) PriMatrix study data validates that one application of PriMatrix is needed to address hard-to-heal diabetic foot ulcers.
Integra's (IART) SurgiMend Gets Innovative Technology Contract
by Zacks Equity Research
Integra's (IART) SurgiMend Collagen Matrix is recognized as a product that can potentially bring improvement to the health care industry.
Integra (IART) Tissue Technologies Rebounds Amid Supply Woe
by Zacks Equity Research
Integra's (IART) CSS segment too reflects a gradual recovery in procedure-based market as well as an improvement in hospital capital spending during the first quarter.
Integra (IART) Down 8.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Integra (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ResMed (RMD) Q3 Earnings Surpass Estimates, Revenues Miss
by Zacks Equity Research
Lower device sales including weak demand for ventilators due to COVID-19 hurt ResMed's (RMD) Q3 top line.
Bio-Rad (BIO) Q1 Earnings Surpass Estimates, Guidance Up
by Zacks Equity Research
Bio-Rad's (BIO) first-quarter revenues improved year over year on robust growth in Life Science and Clinical Diagnostics segments.
Syneos Health (SYNH) Q1 Earnings Top Estimates, Margins Up
by Zacks Equity Research
Syneos Health (SYNH) registers sales uptick in its Clinical Solutions business on the back of favorable acquisition impacts and increased project start-up activities.